Novo Nordisk, Eli Lilly, Sanofi Must Face Insulin Drug Pricing Suit - (Bloomberg via NewsPoints Desk)

  • US District Judge Brian Martinotti ruled that Eli Lilly, Novo Nordisk and Sanofi must face a class action lawsuit accusing the companies of price gouging for their insulin products, Bloomberg reported.

  • Meanwhile, the judge dismissed the plaintiff's racketeering claims.

  • In the case, 67 patients claim that the three drugmakers are illegally raising insulin prices to provide rebates for pharmacy benefit managers, resulting in price hikes exceeding 150 percent over five years.

  • Steve Berman, who is representing the plaintiffs, said the decision "clears the way for us to begin obtaining discovery from the manufacturers and PBMs so we can shine the light on exactly what has driven insulin prices sky-high."

  • "We're pleased with the court's dismissal of the RICO claims and numerous state law claims, and will continue to defend the company against any remaining claims," remarked Novo Nordisk spokesperson Ken Inchausti.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.